Rohit Loomba

101.2k total citations · 65 hit papers
702 papers, 50.7k citations indexed

About

Rohit Loomba is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Rohit Loomba has authored 702 papers receiving a total of 50.7k indexed citations (citations by other indexed papers that have themselves been cited), including 597 papers in Epidemiology, 334 papers in Hepatology and 137 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Rohit Loomba's work include Liver Disease Diagnosis and Treatment (556 papers), Liver Disease and Transplantation (177 papers) and Liver Diseases and Immunity (132 papers). Rohit Loomba is often cited by papers focused on Liver Disease Diagnosis and Treatment (556 papers), Liver Disease and Transplantation (177 papers) and Liver Diseases and Immunity (132 papers). Rohit Loomba collaborates with scholars based in United States, United Kingdom and France. Rohit Loomba's co-authors include Arun J. Sanyal, Claude B. Sirlin, Daniel Q. Huang, Brent A. Neuschwander‐Tetri, Hashem B. El‐Serag, Zobair M. Younossi, David A. Brenner, Siddharth Singh, David E. Kleiner and Manal F. Abdelmalek and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Rohit Loomba

678 papers receiving 50.0k citations

Hit Papers

Farnesoid X nuclear receptor ligand obeticholic acid for ... 2012 2026 2016 2021 2014 2017 2017 2013 2014 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
    2014 1.7k citations Brent A. Neuschwander‐Tetri, Rohit Loomba et al. profile →
  2. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
    2017 1.7k citations Rohit Loomba, Arun J. Sanyal et al. Hepatology profile →
  3. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
    2017 1.3k citations Janki Patel, Vincent Wai‐Sun Wong et al. Hepatology profile →
  4. The global NAFLD epidemic
    2013 1.3k citations Rohit Loomba, Arun J. Sanyal Nature Reviews Gastroenterology & Hepatology profile →
  5. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
    2014 1.2k citations Rohit Loomba et al. profile →
  6. Mechanisms and disease consequences of nonalcoholic fatty liver disease
    2021 1.2k citations Rohit Loomba et al. profile →
  7. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
    2020 1.2k citations Daniel Q. Huang, Rohit Loomba et al. Nature Reviews Gastroenterology & Hepatology profile →
  8. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
    2023 1.2k citations Mary E. Rinella, Brent A. Neuschwander‐Tetri et al. Hepatology profile →
  9. The gut–liver axis and the intersection with the microbiome
    2018 1.0k citations Michael Karin, Rohit Loomba et al. Nature Reviews Gastroenterology & Hepatology profile →
  10. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
    2019 962 citations Rohit Loomba et al. profile →
  11. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
    2021 646 citations Arun J. Sanyal, Brent A. Neuschwander‐Tetri et al. New England Journal of Medicine profile →
  12. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
    2016 573 citations Rohit Loomba et al. profile →
  13. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease
    2016 518 citations Phirum Nguyen, Carolyn Hernandez et al. profile →
  14. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
    2018 452 citations Mohammad Shadab Siddiqui, Brent A. Neuschwander‐Tetri et al. profile →
  15. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
    2017 435 citations Rohit Loomba et al. Hepatology profile →
  16. Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat Fraction to Assess Hepatic Steatosis
    2013 433 citations Rohit Loomba, Claude B. Sirlin et al. profile →
  17. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
    2018 424 citations Arun J. Sanyal, Brent A. Neuschwander‐Tetri et al. profile →
  18. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials
    2013 422 citations Mazen Noureddin, Ricki Bettencourt et al. Hepatology profile →
  19. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
    2017 416 citations Rohit Loomba et al. profile →
  20. Global epidemiology of cirrhosis — aetiology, trends and predictions
    2023 381 citations Daniel Q. Huang, Norah A. Terrault et al. Nature Reviews Gastroenterology & Hepatology profile →
  21. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study
    2014 374 citations Rohit Loomba, Jonathan Hooker et al. Hepatology profile →
  22. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis
    2012 372 citations Rohit Loomba et al. Hepatology profile →
  23. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
    2021 357 citations Vincent Wai‐Sun Wong, Stephen A. Harrison et al. profile →
  24. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
    2024 353 citations Rohit Loomba, Elisabetta Bugianesi et al. New England Journal of Medicine profile →
  25. Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH Trials
    2018 348 citations Cyrielle Caussy, Rohit Loomba et al. Hepatology profile →
  26. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    2018 344 citations Stephen A. Harrison, Mary E. Rinella et al. profile →
  27. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement
    2020 338 citations Rohit Loomba et al. Hepatology profile →
  28. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer
    2022 330 citations Daniel Q. Huang, Darren Jun Hao Tan et al. Cell Metabolism profile →
  29. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants
    2018 295 citations Cyrielle Caussy, Jonathan Hooker et al. profile →
  30. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
    2023 282 citations Rohit Loomba, Arun J. Sanyal et al. profile →
  31. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
    2020 280 citations Arun J. Sanyal, Stephen A. Harrison et al. Hepatology profile →
  32. From NAFLD to MAFLD: Implications of a Premature Change in Terminology
    2020 277 citations Mary E. Rinella, Arun J. Sanyal et al. Hepatology profile →
  33. Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis
    2017 273 citations Cyrielle Caussy, Phirum Nguyen et al. Hepatology profile →
  34. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
    2023 271 citations Rohit Loomba, Arun J. Sanyal et al. New England Journal of Medicine profile →
  35. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
    2020 271 citations Arun J. Sanyal, Rohit Loomba et al. profile →
  36. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
    2019 270 citations Brent A. Neuschwander‐Tetri, Norah A. Terrault et al. profile →
  37. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
    2022 268 citations Daniel Q. Huang, Rohit Loomba et al. Nature Reviews Gastroenterology & Hepatology profile →
  38. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
    2018 257 citations Rohit Loomba, Mazen Noureddin et al. profile →
  39. ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P
    2018 246 citations Peng Zhao, Rohit Loomba et al. profile →
  40. An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
    2020 236 citations Peng Zhao, Xiaoli Sun et al. Science profile →
  41. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review
    2020 233 citations Rohit Loomba et al. profile →
  42. Advances in non-invasive assessment of hepatic fibrosis
    2020 212 citations Rohit Loomba et al. profile →
  43. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
    2023 180 citations Frank Tacke, Rohit Loomba et al. Journal of Hepatology profile →
  44. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
    2021 163 citations Rohit Loomba, Stephen A. Harrison et al. profile →
  45. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
    2022 162 citations Veeral Ajmera, Egbert Madamba et al. Journal of Hepatology profile →
  46. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
    2022 157 citations Naim Alkhouri, Rohit Loomba et al. Journal of Hepatology profile →
  47. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
    2021 152 citations Cyrielle Caussy, Rohit Loomba et al. profile →
  48. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
    2021 146 citations Rohit Loomba et al. Alimentary Pharmacology & Therapeutics profile →
  49. Imaging biomarkers of NAFLD, NASH, and fibrosis
    2021 144 citations Veeral Ajmera, Rohit Loomba profile →
  50. Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease
    2023 144 citations Brent A. Neuschwander‐Tetri, Rohit Loomba et al. Hepatology profile →
  51. Impact of non-invasive biomarkers on hepatology practice: Past, present and future
    2022 129 citations Rohit Loomba et al. Journal of Hepatology profile →
  52. Current therapies and new developments in NASH
    2022 128 citations Elisabetta Bugianesi, Stephen A. Harrison et al. profile →
  53. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
    2022 108 citations Cheng Han Ng, Wen Hui Lim et al. profile →
  54. Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
    2023 102 citations Daniel Q. Huang, Claude B. Sirlin et al. Nature Reviews Gastroenterology & Hepatology profile →
  55. Patterns in Cancer Incidence Among People Younger Than 50 Years in the US, 2010 to 2019
    2023 93 citations Darren Jun Hao Tan, Cheng Han Ng et al. profile →
  56. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    2023 86 citations Monica A. Tincopa, Rohit Loomba profile →
  57. Clinical Trial Landscape in NASH
    2023 77 citations Stephen A. Harrison, Rohit Loomba et al. profile →
  58. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis
    2024 55 citations Mazen Noureddin, Meena B. Bansal et al. profile →
  59. Metabolic dysfunction-associated steatotic liver disease in adults
    2025 53 citations Daniel Q. Huang, Vincent Wai‐Sun Wong et al. profile →
  60. New and emerging treatments for metabolic dysfunction-associated steatohepatitis
    2024 50 citations Monica A. Tincopa, Rohit Loomba et al. Cell Metabolism profile →
  61. From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research
    2024 50 citations Rohit Loomba et al. profile →
  62. Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
    2024 48 citations Tracey G. Simon, Kathleen E. Corey et al. profile →
  63. Lipid-associated macrophages’ promotion of fibrosis resolution during MASH regression requires TREM2
    2024 46 citations Rohit Loomba et al. profile →
  64. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
    2024 44 citations Rohit Loomba, Stephen A. Harrison et al. profile →
  65. The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021
    2025 13 citations Darren Jun Hao Tan, Pojsakorn Danpanichkul et al. Liver International profile →

Peers

Rohit Loomba
Comparison fields: 5 of 191
  • Epidemiology 40.5k
  • Hepatology 20.6k
  • Endocrinology, Diabetes and Metabolism 14.3k
  • Molecular Biology 8.6k
  • Surgery 7.0k
Replace Elizabeth M. Brunt with:
Elizabeth M. Brunt United States
Anna Mae Diehl United States
David E. Kleiner United States
Arthur J. McCullough United States
Vincent Wai‐Sun Wong Hong Kong
Naga Chalasani United States
Zobair M. Younossi United States
Giovanni Targher Italy
Giulio Marchesini Italy
Arun J. Sanyal United States
Elizabeth M. Brunt United States View profile →
Citations per field, relative to Rohit Loomba
Rohit Loomba · 1×
Citations per year, relative to Rohit Loomba
Rohit Loomba · 1×

Countries citing papers authored by Rohit Loomba

Since Specialization
Citations

This map shows the geographic impact of Rohit Loomba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rohit Loomba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rohit Loomba more than expected).

Fields of papers citing papers by Rohit Loomba

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rohit Loomba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rohit Loomba. The network helps show where Rohit Loomba may publish in the future.

Co-authorship network of co-authors of Rohit Loomba

This figure shows the co-authorship network connecting the top 25 collaborators of Rohit Loomba. A scholar is included among the top collaborators of Rohit Loomba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rohit Loomba. Rohit Loomba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
2025 ·Alimentary Pharmacology & Therapeutics ·Mazen Noureddin, Mary E. Rinella, Rebecca Taub, Dominic Labriola, Raul C. Camacho, Naim Alkhouri, Rohit Loomba, Meena B. Bansal
2
2
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
2024 ·Clinical and Molecular Hepatology ·Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
20
3
A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis
2024 ·Cell Metabolism ·Xiang Zhang, Ming‐Hua Zheng, Dehua Liu, Yufeng Lin, Sherlot Juan Song, (unknown), Dabin Liu, Seema Singh, Michael R. Berman, Harry Cheuk-Hay Lau, Hongyan Gou, Grace Lai–Hung Wong, Ni Zhang, (unknown), Rohit Loomba, Vincent Wai‐Sun Wong, Jun Yu
19
4
Pegozafermin, a FGF21 Analog, for the Treatment of Non-alcoholic Steatohepatitis (NASH) Patients with F2/F3 Fibrosis
2024 ·Metabolism ·Deepak L. Bhatt, (unknown), Stephen A. Harrison, Mildred D. Gottwald, Shibao Feng, Germaine D. Agollah, Cynthia L. Hartsfield, Hank Mansbach, Maya Margalit, Rohit Loomba
0
5
WED-212 Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial
2024 ·Journal of Hepatology ·Naim Alkhouri, Shaheen Tomah, John J. Suschak, (unknown), M. Scot Roberts, (unknown), Sarah Browne, Rohit Loomba
1
6
Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
2024 ·Alimentary Pharmacology & Therapeutics ·Nobuharu Tamaki, Takefumi Kimura, (unknown), Takeji Umemura, (unknown), Rohit Loomba, Namiki Izumi
25
7
Machine learning uncovers manganese as a key nutrient associated with reduced risk of steatotic liver disease
2024 ·Liver International ·(unknown), Kate Townsend Creasy, (unknown), Jan Clusmann, (unknown), (unknown), Alexander Koch, Christian Trautwein, Rohit Loomba, Tom Luedde, Kai Markus Schneider, Carolin V. Schneider
7
8
Global epidemiology of cirrhosis — aetiology, trends and predictions breakdown →
2023 ·Nature Reviews Gastroenterology & Hepatology ·Daniel Q. Huang, Norah A. Terrault, Frank Tacke, Lise Lotte Gluud, Marco Arrese, Elisabetta Bugianesi, Rohit Loomba
381
9
Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality
2023 ·Alimentary Pharmacology & Therapeutics ·Sung Won Lee, Daniel Q. Huang, Ricki Bettencourt, Veeral Ajmera, Monica A. Tincopa, Nabil Noureddin, (unknown), Harris Siddiqi, Egbert Madamba, Abdul M. Majzoub, Tarek Nayfeh, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Masato Yoneda, (unknown), Mesut Gümüşsoy, Diğdem Kuru Öz, Ayşe Erden, Rohit Loomba
6
10
Review article: Available modalities for screening and imaging diagnosis of hepatocellular carcinoma—Current gaps and challenges
2023 ·Alimentary Pharmacology & Therapeutics ·(unknown), George N. Ioannou, Claude B. Sirlin, Rohit Loomba
8
11
The silent burden of non‐alcoholic fatty liver disease in the elderly: A global burden of disease analysis
2023 ·Alimentary Pharmacology & Therapeutics ·Pojsakorn Danpanichkul, Cheng Han Ng, Mark Muthiah, Kwanjit Duangsonk, Jie Ning Yong, Darren Jun Hao Tan, Wen Hui Lim, Zhen Yu Wong, Nicholas Syn, (unknown), Hirokazu Takahashi, Mohammad Shadab Siddiqui, Vincent Wai‐Sun Wong, Christos S. Mantzoros, Daniel Q. Huang, Mazen Noureddin, Rohit Loomba, Arun J. Sanyal, Karn Wijarnpreecha
17
12
Fazirsiran for Liver Disease Associated with Alpha 1 -Antitrypsin Deficiency
2022 ·New England Journal of Medicine ·Pavel Strnad, Mattias Mandorfer, Gourab Choudhury, William J. Griffiths, Christian Trautwein, Rohit Loomba, Thomas Schluep, Ting Chang, Min Yi, Bruce D. Given, James Hamilton, Javier San Martín, Jeffrey Teckman
65
13
Risk assessment with gut microbiome and metabolite markers in NAFLD development
2022 ·Science Translational Medicine ·(unknown), Xiaoxue Long, Yueqiong Ni, Lingling Qian, (unknown), (unknown), (unknown), Kati Hanhineva, Yan Liu, Aimin Xu, Henrik Bjørn Nielsen, Eugeni Belda, Karine Clément, Rohit Loomba, Huating Li, Weiping Jia, Gianni Panagiotou
91
14
Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD
2021 ·Physiological Genomics ·Na Jiao, Rohit Loomba, Zihuan Yang, Dingfeng Wu, (unknown), Richele Bettencourt, Ping Lan, Ruixin Zhu, Lixin Zhu
20
15
Machine learning enables new insights into genetic contributions to liver fat accumulation
2021 ·Cell Genomics ·Mary E. Haas, James P. Pirruccello, Sam Friedman, Minxian Wang, Connor A. Emdin, Veeral Ajmera, Tracey G. Simon, Julian R. Homburger, Xiuqing Guo, Matthew J. Budoff, Kathleen E. Corey, Alicia Y. Zhou, Anthony Philippakis, Patrick T. Ellinor, Rohit Loomba, Puneet Batra, Amit V. Khera
55
16
Persistent Right Venous Valve: Insights From Multimodality Imaging
2021 ·Circulation Cardiovascular Imaging ·(unknown), (unknown), (unknown), Rohit Loomba, Natesa G. Pandian, Shelby Kutty
7
17
An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis breakdown →
2020 ·Science ·Peng Zhao, Xiaoli Sun, (unknown), Zhongji Liao, (unknown), Feng He, Seema Singh, Rohit Loomba, Michael Karin, Joseph L. Witztum, Alan R. Saltiel
236
18
Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis breakdown →
2017 ·Hepatology ·Cyrielle Caussy, (unknown), Phirum Nguyen, Carolyn Hernandez, (unknown), (unknown), Veeral Ajmera, Ricki Bettencourt, (unknown), Jonathan Hooker, Ethan Sy, Emily Rizo, Lisa Richards, Claude B. Sirlin, Rohit Loomba
273
19
Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study
2017 ·Contemporary Clinical Trials ·A. Sidney Barritt, Norman Gitlin, Samuel Klein, Anna S. Lok, Rohit Loomba, (unknown), (unknown), Miriam B. Vos, Laurence Weiss, Kenneth Cusi, Brent A. Neuschwander‐Tetri, Arun J. Sanyal
39
20
Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis
2016 ·Therapeutic Advances in Gastroenterology ·Janki Patel, Ricki Bettencourt, Jeffrey Cui, Joanie Salotti, Jonathan Hooker, Archana Bhatt, Carolyn Hernandez, Phirum Nguyen, Hamed Aryafar, Mark A. Valasek, William Haufe, Catherine A. Hooker, Lisa Richards, Claude B. Sirlin, Rohit Loomba
130

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth M. Brunt Breakdown of academic impact, for papers by Anna Mae Diehl Breakdown of academic impact, for papers by David E. Kleiner Breakdown of academic impact, for papers by Arthur J. McCullough Breakdown of academic impact, for papers by Vincent Wai‐Sun Wong Breakdown of academic impact, for papers by Naga Chalasani Breakdown of academic impact, for papers by Zobair M. Younossi Breakdown of academic impact, for papers by Giovanni Targher Breakdown of academic impact, for papers by Giulio Marchesini Breakdown of academic impact, for papers by Arun J. Sanyal
Rankless by CCL
2026